Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans.
Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans.
复制标题
DOI：
10.1016/j.jnma.2023.01.008
复制
发表时间：
2023-04
影响因子：
3.3
通讯作者：
Rogers, Sherise C.
中科院分区：
文献类型：
--
作者：
Telisnor, Guettchina;DeRemer, David L.;Frimpong, Esther;Agyare, Edward;Allen, John;Ricks-Santi, Luisel;Han, Bo;George, Thomas;Rogers, Sherise C.
胰腺导管腺癌（PDAC）目前是癌症死亡的第三大原因，预计到2030年发病率将增加。尽管最近在治疗方面取得了进展，但与欧洲裔美国人相比，非洲裔美国人的发病率高出50-60%，死亡率高出30%，这可能是由于社会经济地位，获得医疗保健和遗传学的差异。遗传学在癌症易感性、对癌症治疗的反应（药物遗传学）和肿瘤行为中起作用，使一些基因成为肿瘤治疗的靶点。我们假设，在易感性、药物反应和靶向治疗方面的生殖系遗传差异也会影响PDAC差异。为了证明遗传学和药物遗传学对PDAC差异的影响，使用PubMed进行了文献综述，其中包含以下关键词的变体：药物遗传学、胰腺癌、人种、种族、非洲人、黑人、毒性和FDA批准的药物名称：氟尿嘧啶、拓扑异构酶抑制剂、吉西他滨、Nab-紫杉醇、铂类药物、Pembrolizumab、PARP抑制剂和NTRK融合抑制剂。我们的研究结果表明，非洲裔美国人的遗传特征可能有助于FDA批准的PDAC患者化疗反应的差异。我们建议重点关注改善非裔美国人的基因检测和参与生物库样本捐赠。通过这种方式，我们可以提高我们目前对影响PDAC患者药物反应的基因的理解。
Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite recent advances in its treatment, African Americans have a 50-60% higher incidence and 30% higher mortality rate when compared to European Americans possibly resulting from differences in socioeconomic status, access to healthcare, and genetics. Genetics plays a role in cancer predisposition, response to cancer therapeutics (pharmacogenetics), and in tumor behavior, making some genes targets for oncologic therapeutics. We hypothesize that the germline genetic differences in predisposition, drug response, and targeted therapies also impact PDAC disparities. To demonstrate the impact of genetics and pharmacogenetics on PDAC disparities, a review of the literature was performed using PubMed with variations of the following keywords: pharmacogenetics, pancreatic cancer, race, ethnicity, African, Black, toxicity, and the FDA-approved drug names: Fluoropyrimidines, Topoisomerase inhibitors, Gemcitabine, Nab-Paclitaxel, Platinum agents, Pembrolizumab, PARP-inhibitors, and NTRK fusion inhibitors. Our findings suggest that the genetic profiles of African Americans may contribute to disparities related to FDA approved chemotherapeutic response for patients with PDAC. We recommend a strong focus on improving genetic testing and participation in biobank sample donations for African Americans. In this way, we can improve our current understanding of genes that influence drug response for patients with PDAC.
登录
查看更多内容
影响因子：
1.5
作者：
Cook ED;Yeager KA;Cecchini RS;Boparai J;Brown CL;Duncan M;Cronin WM;Paskett ED
通讯作者：
Paskett ED
DOI：
10.1097/00008571-200110000-00006
发表时间：
2001-10-01
期刊：
PHARMACOGENETICS
影响因子：
--
作者：
Dai, D;Zeldin, DC;Goldstein, JA
通讯作者：
Goldstein, JA
影响因子：
12.6
作者：
Berera, Shivali;Koru-Sengul, Tulay;Sussman, Daniel A.
通讯作者：
Sussman, Daniel A.
影响因子：
3.9
作者：
Baker, Jessica A. Roseberry;Wickremsinhe, Enaksha R.;Guo, Yingying
通讯作者：
Guo, Yingying
影响因子：
3.7
作者：
Carethers, John M.;Murali, Bhavya;McGuire, Kathleen L.
通讯作者：
McGuire, Kathleen L.